Jefferies Group LLC Bristol Myers Squibb CO Transaction History

Jefferies Group LLC

$10.2 Billion
Q3 2022

A detailed history of Jefferies Group LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Jefferies Group LLC holds 89,300 shares of BMY stock, worth $4.38 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

89,300

Previous 44,000 102.95%

Holding current value

$4.38 Million

Previous $3.39 Million 87.37%

% of portfolio

0.06%

Previous 0.03%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $5,574 - $3.3 Million	-42,882 Reduced 97.46%	1,118 $2,000
Q2 2022 Sep 21, 2023	BUY	$72.62 - $79.98 $490,185 - $539,865	6,750 Added 18.12%	44,000 $3.39 Million
Q2 2022 Aug 15, 2022	BUY	$72.62 - $79.98 $324,756 - $357,670	4,472 Added 11.31%	44,000 $3.39 Million
Q1 2022 Sep 21, 2023	BUY	$61.48 - $73.72 $46,110 - $55,290	750 Added 2.05%	37,250 $2.72 Million
Q1 2022 May 16, 2022	SELL	$61.48 - $73.72 $606,992 - $727,837	-9,873 Reduced 19.99%	39,528 $2.73 Million
Q4 2021 Sep 21, 2023	SELL	$53.63 - $62.52 $8.39 Million - $9.78 Million	-156,350 Reduced 81.07%	36,500 $2.28 Million
Q4 2021 Feb 14, 2022	SELL	$53.63 - $62.52 $7.69 Million - $8.97 Million	-143,449 Reduced 74.38%	49,401 $2.65 Million
Q3 2021 Sep 21, 2023	BUY	$59.17 - $69.31 $10.6 Million - $12.4 Million	178,436 Added 1237.94%	192,850 $11.4 Million
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $10.6 Million - $12.4 Million	178,436 Added 1237.94%	192,850 $11.4 Million
Q2 2021 Sep 21, 2023	BUY	$61.91 - $67.42 $640,025 - $696,987	10,338 Added 253.63%	14,414 $963,000
Q2 2021 Aug 16, 2021	BUY	$61.91 - $67.42 $640,025 - $696,987	10,338 Added 253.63%	14,414 $963,000
Q1 2021 Sep 21, 2023	SELL	$59.34 - $66.74 $577,200 - $649,179	-9,727 Reduced 70.47%	4,076 $257,000
Q1 2021 May 14, 2021	SELL	$59.34 - $66.74 $577,200 - $649,179	-9,727 Reduced 70.47%	4,076 $257,000
Q4 2020 Sep 21, 2023	BUY	$57.74 - $65.43 $732,431 - $829,979	12,685 Added 1134.62%	13,803 $856,000
Q4 2020 Feb 16, 2021	BUY	$57.74 - $65.43 $754,950 - $855,497	13,075 Added 1796.02%	13,803 $856,000
Q3 2020 Nov 13, 2020	SELL	$57.43 - $63.64 $23,374 - $25,901	-407 Reduced 35.86%	728 $44,000
Q2 2020 Aug 14, 2020	SELL	$54.82 - $64.09 $5.6 Million - $6.55 Million	-102,239 Reduced 98.9%	1,135 $67,000
Q1 2020 May 15, 2020	SELL	$46.4 - $67.43 $10.2 Million - $14.8 Million	-219,669 Reduced 68.0%	103,374 $5.76 Million
Q4 2019 Feb 13, 2020	BUY	$49.21 - $64.19 $9.47 Million - $12.3 Million	192,382 Added 147.24%	323,043 $20.7 Million
Q3 2019 Nov 13, 2019	SELL	$42.77 - $50.71 $7.18 Million - $8.51 Million	-167,909 Reduced 56.24%	130,661 $6.63 Million
Q2 2019 Aug 14, 2019	SELL	$44.62 - $49.34 $3.2 Million - $3.54 Million	-71,649 Reduced 19.35%	298,570 $13.5 Million
Q1 2019 May 15, 2019	BUY	$45.12 - $53.8 $15.4 Million - $18.3 Million	340,745 Added 1156.09%	370,219 $17.7 Million
Q4 2018 Feb 14, 2019	BUY	$48.76 - $63.23 $9,605 - $12,456	197 Added 0.67%	29,474 $1.53 Million
Q3 2018 Nov 14, 2018	BUY	$55.19 - $62.25 $1.49 Million - $1.68 Million	27,038 Added 1207.59%	29,277 $1.82 Million
Q2 2018 Aug 14, 2018	SELL	$50.53 - $62.98 $1.95 Million - $2.44 Million	-38,677 Reduced 94.53%	2,239 $124,000
Q1 2018 May 15, 2018	SELL	$59.92 - $68.98 $11 Million - $12.7 Million	-183,771 Reduced 81.79%	40,916 $2.59 Million
Q4 2017 Feb 14, 2018	BUY	$59.94 - $65.35 $1.64 Million - $1.79 Million	27,386 Added 13.88%	224,687 $13.8 Million
Q3 2017 Nov 14, 2017	BUY	$55.23 - $63.74 $10.9 Million - $12.6 Million	197,301	197,301 $12.6 Million

Others Institutions Holding BMY

# of Institutions

2,810

Shares Held

1.59B

Call Options Held

25.9M

Put Options Held

23.9M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $104B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Group LLC with notifications on news.

Account

Jefferies Group LLC Bristol Myers Squibb CO Transaction History